SN//Connect

Practical Guidance on Mental Health and Physician Burnout

Latest News

How Top Institutions Are Working to Reduce Racial Disparities

Black Americans have a two- to three-fold incidence of multiple myeloma compared to whites, yet they are significantly underrepresented in clinical trials. Issues with access, eligibility, and a lack of information from providers prevent many Black patients from participating.

Learn More

What We’re Learning About Isatuximab and How It’s Being Used to Treat Multiple Myeloma Patients

The recent FDA approval of isatuximab in combination with pomalidomide and dexamethasone has opened up another avenue of treatment for multiple myeloma patients who have already undergone two prior lines of therapy.

Learn More

Belamaf is ‘First-In-Class’ New Therapy for Relapsed/Refractory Myeloma, But What’s Its Role in the Toolkit?

In August, the FDA granted belantamab mafodotin (Belamaf) accelerated approval for patients with relapsed or refractory multiple myeloma who've received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Learn More

Next Level HRD Testing and How to Make Better Decisions

Dr. Thomas Herzog notes the importance of an HRD test, “Getting an HRD for me would be important. I think the next gen sequencing doesn’t lead to new treatments all that often. My counter-argument to that is that we’re learning more and more. We really want to move the field forward and we need to get that information."

Learn More

Has COVID-19 Changed Treatment?

Many oncologists are wondering: How has COVID-19 changed treatment? Dr. Elizabeth Jewell of Memorial Sloan Kettering says, “You can safely get COVID-positive patients and cancer patients through treatment and through surgery.” Many are following ACS guidelines around how to stratify cases.

Learn More

Practical Steps for Physician Burnout

Therapy for physicians is important. Providers can be consumers of therapy, and there should be no shame in seeking help. Dr. Elizabeth Jewell says to identify risk factors. “Middle-aged women, and associate professors tend to be high risk [for mental health issues]. A lot of it has to do with busier clinical practices, job expectations, and responsibilities at home. As a society, we need to figure that out.”

Learn More

Should PARP Inhibitors Be Offered to All Women?

When it comes to PARP inhibitors, Dr. Rebecca Arend of the University of Alabama says, “The message is not that each patient should get a PARP inhibitor no matter what, but that it is an awareness that we need to put out into the community.”

Learn More

‘Exciting’ New Therapies, Including BTK Inhibitors and Monoclonal Antibodies, Promising for CLL

In recent years, the treatment of chronic lymphocytic leukemia (CLL) has undergone a seismic shift, with chemotherapy being replaced by a new and more effective generation of drugs. One of the "really exciting" therapies to emerge is the Bruton's tyrosine kinase inhibitors.

Learn More